Sinopharm Group Co. Ltd.

DB:X2S1 Stock Report

Market Cap: €7.6b

Sinopharm Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Wanyong Lian

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.7yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

CEO

Wanyong Lian (53 yo)

less than a year

Tenure

Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...

Leadership Team

NamePositionTenureCompensationOwnership
Wanyong Lian
President & Executive Directorless than a yearno datano data
Xiaojuan Li
Chief Financial Officer3.7yrsno datano data
Yijian Wu
Secretary to the Board5.9yrsno datano data

3.7yrs

Average Tenure

53yo

Average Age

Experienced Management: X2S1's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wanyong Lian
President & Executive Directorless than a yearno datano data
Qiyu Chen
Non-Executive Vice Chairman14.5yrsno datano data
Dongjiu Li
Non-Executive Director3.4yrsno datano data
Xiaohui Guan
Chief Supervisor3.4yrsno datano data
Tak Lung Wu
Independent Non-Executive Director4.2yrsCN¥350.00kno data
Peiyu Li
Independent Non-Executive Director4.2yrsCN¥350.00kno data
Bingxiang Zhao
Non-Executive Chairmanless than a yearno datano data
Deyong Wen
Non-Executive Director7.2yrsno datano data
Fangruo Chen
Independent Non-Executive Director5.9yrsCN¥350.00kno data
Rongli Feng
Non Executive Director4.4yrsno datano data
Weifeng Yu
Independent Non-Executive Director4.2yrsCN¥350.00kno data
Peng Wang
Non-executive Director1.2yrsno datano data

4.2yrs

Average Tenure

53yo

Average Age

Experienced Board: X2S1's board of directors are considered experienced (4.2 years average tenure).